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SmokersAbstract Background: Inﬂammation of the airways is present in COPD with increased number of
inﬂammatory cells including killer cells that lyse their target cells by two mechanisms; membranol-
ysis in which secreted molecules such as granzymes form pores in the membrane of target cells; and
apoptosis. Granzyme B has the strongest apoptotic activity of all granzymes.
Aim of this work: Aim of this work was to study the relation between Granzyme B, tobacco
smoking and chronic obstructive pulmonary disease.
Methods: The study included 40 clinically stable COPD patients classiﬁed according to GOLD
(2013) criteria into two groups; moderate (GOLD II) and severe (GOLD III) plus 40 apparently
healthy control subjects (20 smokers and 20 nonsmokers). Pulmonary function results and serum
levels of Granzyme B (measured by ELISA) were recorded.
Results: Granzyme B levels are elevated in COPD. Cigarette smoking appears to be a direct
stimulus to Granzyme B production. Granzyme B could play a role in the pathogenesis of COPD.
Aging seems to be a risk factor for Granzyme B production and pathogenesis of COPD.
Conclusion: Granzyme B levels are elevated in COPD. Cigarette smoking appears to be a direct
stimulus to Granzyme B production. Granzyme B could play a role in the pathogenesis of COPD.
Aging seems to be a risk factor for Granzyme B production and pathogenesis of COPD.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.Introduction
Chronic obstructive pulmonary disease (COPD) is an incapac-
itating, highly prevalent airway disease that arises as a result of
noxious injury to the lungs, most commonly due to cigarette
smoking. The disease causes serious morbidity and mortality
816 A.A. Yousef et al.[11]. Cigarette smoking is by far the most important risk factor
for COPD. However, only a susceptible minority (15–20%) of
tobacco smokers develops clinically signiﬁcant COPD, sug-
gesting that genetic factors (such as the rare hereditary deﬁ-
ciency of a1-antitrypsin) must modify each individual’s risk.
Although the major environmental risk factor for COPD –
tobacco smoke – is well known since many years, the cellular
and molecular mechanisms that are involved in the pathogen-
esis of COPD have not yet been fully elucidated [1]. Recently,
it has been reported that soluble Granzyme B levels and the
proportion of T cells expressing intracellular Granzyme B or
perforin were increased in the BAL of both current and
ex-smokers with COPD [4]. Granzyme B is proposed to play
a role in pathogenesis of chronic obstructive pulmonary
disease [8].
Subjects and methods
Eighty subjects were included in this study which comprised of
forty COPD patients and forty age matched apparently
healthy subjects as controls. This study was carried out at
the Chest department of the Benha University Hospital from
April 2011 to May 2012.
Inclusion criteria
1. All COPD patients and healthy smoker controls must be
current heavy cigarette smokers.
2. By spirometry: post bronchodilator improvement in FEV1
is less than 12% in all patients.
3. Patients should be in a stable state and not in exacerbations.
Exclusion criteria
1. History of cancer in the past ﬁve years.




6. Collagen vascular diseases.
7. Non-COPD pulmonary conditions.20 of COPD patients
were in GOLD (2011) stage II (moderate) while the other
20 patients were in stage III (severe). 20 of the healthy
subjects were heavy cigarette smokers while the other 20
were never smokers.
All cases were subjected to the following:
1. Full history taking including:History of smoking and its severity by smoking index
(number of packs/day · number of years smoking).
History of other co-morbidities that may affect the level
of Granzyme B.
2. Clinical examination:
General and local examination.
3. Laboratory investigations:Fasting and 2 h post prandial blood glucose.
Kidney function tests.
Liver function tests.
4. Radiological examination:Plain postero-anterior and lateral chest X-rays were
done to exclude any chest lesion if present.
5. Ventilatory function test (spirometry):Done before and after bronchodilatation.
6. Collection and processing of blood sample [9]:
a. Venous blood samples were taken from arm veins in
the right way and labeled with patient name and
number.
b. Serum preparation: Serum is obtained by allowing the
blood to clot in the original closed container at room
temperature (20–30 min). Centrifugation for serum is
10 min at an RCF of 1000 in the stoppered container.
7. Granzyme B assay (Granzyme B ELISA kit by Abcam,
Cambridge, England, ab46142):
a. Principle of assay method:Granzyme B kit is a solid
phase sandwich Enzyme Linked-Immuno-Sorbent
Assay (ELISA). A monoclonal antibody speciﬁc for
Granzyme B has been coated onto the wells of the
microtiter strips provided. Samples, including stan-
dards of unknown Granzyme B concentrations and
unknowns are pipetted into these wells. During the ﬁrst
incubation, the Granzyme B antigen and a biotinylated
monoclonal antibody speciﬁc for Granzyme B are
simultaneously incubated. After washing, the enzyme
(streptavidin-peroxidase) is added. After incubation
and washing to remove all unbound enzyme, a sub-
strate solution which is acting on the bound enzyme
is added to induce a colored reaction product. The
intensity of this colored product is directly propor-
tional to the concentration of Granzyme B present in
the samples.
b. Data analysis:Generate a linear standard curve by plot-
ting the average absorbance on the vertical axis versus
the corresponding Granzyme B standard concentration
on the horizontal axis. The amount of Granzyme B in
each sample is determined by extrapolating O.D. values
toGranzyme B concentrations using the standard curve.Results
Tables 1–10
Discussion
The results in the present study as regards age and sex were in
agreement with Peder et al. In their survey, they studied the
prevalence of COPD in Copenhagen and included 6236 partic-
ipants. All non-COPD participants aged 35 years or older with
adequate lung function data were included for the ﬁnal preva-
lence analyses. COPD staging was done according to the
GOLD criteria. They found that COPD prevalence increases
with age and was higher among males.
Granzyme B values were higher in patients than in controls.
Values were also higher in severe disease (GOLD III) than in
moderate disease (GOLD II). Also, Granzyme B values were
higher in smoker controls than in nonsmoker controls.
In the present study, Granzyme B values were signiﬁcantly
higher in patients than in controls (p< 0.001) (Table 4). This
result is supported by the work of Hodge et al. [4] who studied
intracellular Granzyme B in blood derived cytotoxic T
Table 1 Age and sex distribution in COPD patients.
Moderate group I Severe group II All patients
– Age
 Mean 52.8 67.7 60.25
 SD 5.96 8.26 10.37
 Range
30–49 6 0 6
50–79 14 19 33
P80 1 1 1
– Sex
 Male 19 (95%) 20 (100%) 39 (97.5%)
 Female 1 (5%) 0 (0%) 1 (2.5%)
The table shows that the majority of patients were in 6th, 7th and
8th decades of life.
All patients were males except a female.








 Mean 45.4 44.3 44.85
 SD 6.52 7.28 6.76
 Range
30–49 13 13 26
50–79 7 7 14
P80 0 0 0
– Sex
 Male 20 (100%) 19 (95%)P 80 39 (97.5%)
 Female 0 (0%) 1 (5%) 1 (2.5%)
The table shows that controls studied were between 4th and 8th
decades of life. All controls were males except a female.
Table 3 Descriptive statistics of Granzyme B (pg/ml).
Mean ± SD Range N
Patients 287.08 ± 118.43 70.1–568.1 40
Controls 88.65 ± 59.68 0–226 40
Severe COPD 346.21 ± 109.76 167.54–568.1 20
Moderate COPD 227.95 ± 96.85 70.1–384.06 20
Smoker controls 127.99 ± 54 57.11–226 20
Nonsmoker controls 49.3 ± 33.7 0–111.25 20
The table shows statistical values of Granzyme B (pg/ml) in dif-
ferent groups studied.
Table 4 Comparison of Granzyme B (pg/ml) between patients
and controls.
Groups Mean ± SD Range Mean diﬀ. t p
Patients 287.08 ± 118.43 70.1–568.1 198.43 10.91 0.00
Controls 88.65 ± 59.68 0–226
The table shows that Granzyme B levels were signiﬁcantly higher in
patients than controls.
Table 5 Comparison of Granzyme B between severe and
moderate COPD.
Groups Mean ± SD Range Mean diﬀ. t p
Severe
COPD
346.21 ± 109.76 167.45–568.1 118.264 5.38 0.00
Moderate
COPD
227.946 ± 96.85 70.1–384.06
The table shows that Granzyme B levels were signiﬁcantly higher in
severe COPD patients than those with moderate disease.
Serum Granzyme B in heavy cigarette smokers 817lymphocytes and Natural Killer cells in COPD subjects and
asymptomatic controls. In blood there was a signiﬁcant
increased expression of Granzyme B in cytotoxic T lympho-
cytes in COPD than in healthy controls. Most circulating
NK cells expressed Granzyme B, with the median ﬂuorescence
intensity of staining increased in both COPD groups and
asymptomatic smokers. Hodge et al. [4] also studied the per-
centage of T cells expressing Granzyme B in bronchoalveolar
lavage. There was a signiﬁcant correlation between Granzyme
B expression in BAL and apoptosis of bronchial epithelial
cells. As regards the role of Granzyme B in COPD severity,
the results in the present study show that Granzyme B values
were signiﬁcantly higher in severe COPD (GOLD III) than
in moderate (GOLD II) patients (p< 0.001) (Table 5). These
results agree with Vickerman et al. [13]. The main objective of
the study done by Vickerman et al. [13] was to assess the rela-
tion between plasma Granzyme B level and the severity of
COPD. Plasma Granzyme B was measured in 100 COPD
patients (mean age 67 ± 8; mean FEV1% 47 ± 23%) by
ELISA; 50 with GOLD II disease and 50 with GOLD III
and IV disease. They detected increasing plasma Granzyme
B levels in more advanced cases of COPD (GOLD III and
IV) compared to less severe cases. Urbanowicz et al. [12] stud-
ied the cytotoxic activity of NK cells in smoker COPD
patients, healthy smokers and healthy nonsmokers. In this
study, proportions of NK cells expressing Granzyme B were
signiﬁcantly higher in COPD patients than in healthy controls.
Also the proportions of same cells were signiﬁcantly higher in
healthy smokers than in nonsmokers. They also studied the
correlation between the proportions of NK cells expressing
Granzyme B and FEV1% where an inverse relation was
detected between them. This inverse relation supports our
result in which Granzyme B was signiﬁcantly higher in patients
with severe disease (GOLD III) than those with moderate dis-
ease (GOLD II) (p< 0.001) (Table 5). Results of Urbanowicz
et al. [12] also support our ﬁnding of a signiﬁcant inverse rela-
tion between FEV1% and Granzyme B was detected in
patients (p< 0.001) and smoker controls (p< 0.05) (Table 7).
A signiﬁcant inverse relation was also detected between
FEF25–75% and Granzyme B in patients (p< 0.001) and
smoker controls (p< 0.05) (Table 8) indicating that Gran-
zyme B is not only related to disease severity but also related
to small airway disease. Contrary to our results, Morissette
et al. [7] studied Granzyme B in T lymphocytes derived from
blood and found no relation between Granzyme B and COPD
severity. Twenty-nine subjects matched for age and sex were
included in their study: nine were active smokers with evidence
of emphysema and airﬂow limitation deﬁned according to
the GOLD criteria (FEV1 < 80% predicted value, FEV1
/FVC < 70% predicted value, and reversibility 6 12% and
Table 7 Correlation between FEV1% and Granzyme B (pg/
ml).
R t p
Patients (All) 0.698 6.013 0.000
Controls (All) 0.519 3.739 0.001
Severe COPD 0.499 2.446 0.025
Moderate COPD 0.698 4.134 0.001
Smoker controls 0.546 2.764 0.013
Nonsmoker controls 0.137 0.587 0.565
The table shows a signiﬁcant inverse relation between FEV1% and
Granzyme B (pg/ml) in all groups except non smoker controls
where no signiﬁcant relation was observed.
Table 8 Correlation between FEF25–75% and Granzyme B
(pg/ml).
R t p
Patients (All) 0.711 6.235 0.000
Controls (All) 0.700 6.044 0.000
Severe COPD 0.668 3.804 0.001
Moderate COPD 0.565 2.903 0.009
Smoker controls 0.474 2.286 0.035
Non smoker controls 0.048 0.203 0.841
The table shows a signiﬁcant inverse relation between FEF25–75%
and Granzyme B in all groups except for nonsmoker control group
where no signiﬁcant relation was observed.
Table 9 Correlation between age and Granzyme B.
R t p
Patients (All) 0.674 5.626 0.000
Controls (All) 0.637 5.094 0.000
Severe COPD 0.472 2.271 0.036
Moderate COPD 0.595 3.142 0.006
Smoker controls 0.548 2.782 0.012
Non smoker controls 0.118 0.505 0.619
The table shows a signiﬁcant direct relation between age and
Granzyme B (pg/ml) in patients and smoker control groups, but no
signiﬁcant relation was detected in nonsmoker control group.
Table 6 Comparison of Granzyme B between moderate COPD and smoker controls.
Groups Mean ± SD Range Mean diﬀ. t p
Moderate COPD 227.946 ± 96.85 70.1–384.06 99.95 3.934 0.001
Smoker controls 127.99 ± 54 57.11–226
The table shows that Granzyme B (pg/ml) level was signiﬁcantly higher in patients with moderate COPD than smoker controls.
Table 10 Correlation between smoking index and Granzyme
B (pg/ml).
R t p
Patients (All) 0.740 6.790 0.000
Severe COPD 0.694 4.085 0.001
Moderate COPD 0.662 3.749 0.001
Smoker controls 0.498 2.438 0.025
The table shows a signiﬁcant direct relation between smoking index
and Granzyme B (pg/ml) in patients, and smoker control group.
818 A.A. Yousef et al.200 ml after salbutamol inhalation), 10 were smokers with nor-
mal lung function, and 10 were nonsmokers with normal lung
function. In subjects with airﬂow limitation, the presence of
emphysema was further conﬁrmed by a radiologist following
CT scanning analyses and a diffusion capacity (DLCO)
<80% predicted value for men and <70% predicted value
for women. Subjects were excluded from the study if they have
a history of cancer in the past ﬁve years, active liver, heart orkidney disease, diabetes or any other non-emphysematous pul-
monary condition. There was no signiﬁcant difference in Gran-
zyme B levels between all groups.
The present study detected a signiﬁcant direct relation
between age and Granzyme B both in patients (p< 0.001)
and smoker control (p< 0.05) groups (Table 9). This result
is supported by Janssens et al. [6] who mentioned that alveolar
dilatation and impairment of gas exchange are linked with
lung aging, and the expression of Granzyme B in type II pneu-
mocytes and also stated that alveolar macrophages may repre-
sent one contributing mean by which alveolar cell apoptosis
occurs. Also, in support to our result, Boivin et al. [2] men-
tioned that Granzyme B is associated with pathogenesis of
other aging related diseases such as atherosclerosis and skin
wrinkling. It is noted by Rahman and Adcock [10] that reac-
tive oxygen species, such as those derived from cigarette
smoke, drive inﬂammation via activation of redox-sensitive
transcription factors, including nuclear factor-kB (NFkB)
and activator protein-1, which in turn promote the upregula-
tion of several pro-inﬂammatory molecules. The consequent
enhanced inﬂammation would purportedly perpetuate the
accelerated aging process through the activation of apoptotic
pathways by mediators such as Granzyme B.
The classical epidemiologic studies of Fletcher and Peto [3]
demonstrated that death and disability from COPD were
related to an accelerated decline in lung function with time,
with a loss of 50 to 100 ml in FEV1 per year, but even in
healthy volunteers there is a loss of 20 ml per year with aging.
Janssens et al. [6] demonstrated that physiologic aging of the
lung is associated with dilatation of alveoli with an enlarge-
ment of airspaces and a decrease in gas exchange surface area,
together with a loss of supporting tissue for peripheral airways
(‘‘senile emphysema’’), resulting in decreased static elastic
recoil of the lung and increased residual volume and functional
residual capacity. This age-dependent loss of elastin ﬁbers is
similar to the loss of skin elasticity and wrinkling of the skin
that occurs with age. Thus, aging lungs exhibit both structural
and functional alterations [5].
In the present study, a signiﬁcant direct relation was detected
between Granzyme B values and smoking index in patients
(p< 0.001) and smoker controls (p< 0.05) (Table 10).
Serum Granzyme B in heavy cigarette smokers 819Hodge et al. [4] studied Granzyme B and perforins in
current and ex-smoker COPD. They measured granzyme levels
intracellularly in T-cells isolated from blood and BAL as well
as soluble levels in BAL. They found soluble levels to be
increased in BAL both in smoker COPD as well as asymptom-
atic smokers which supports our result. They also found
persistence of apoptotic activity induced by granzymes after
smoking cessation.
On the other hand, Morissette et al. [7] found no difference
between emphysematous smokers, normal smokers and
normal nonsmoker subjects in expression of Granzyme B by
T-lymphocytes.
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